Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12714343 | 0.86 | TDP1 (0.39) | TDP1ALDH1A1KCNJ1KDM4EMAPT | |
| SCHEMBL11900275 | 0.81 | TDP1 (0.43) | TDP1ALDH1A1KCNJ1KDM4EMAPT | |
| SCHEMBL31595924 | 0.78 | TDP1 (0.41) | TDP1ALDH1A1KCNJ1KDM4EMAPT | |
| SCHEMBL2520194 | 0.78 | TDP1 (0.41) | TDP1ALDH1A1KCNJ1KDM4EMAPT | |
| SCHEMBL31595820 | 0.78 | TDP1 (0.41) | TDP1ALDH1A1KCNJ1KDM4EMAPT | |
| SCHEMBL2517149 | 0.74 | TDP1 (0.38) | TDP1ALDH1A1KCNJ1KDM4EMAPT | |
| SCHEMBL9568936 | 0.73 | ALDH1A1 (0.42) | TDP1ALDH1A1KCNJ1KDM4EMAPT | |
| SCHEMBL29552740 | 0.73 | — | — | |
| SCHEMBL30036163 | 0.72 | TDP1 (0.37) | TDP1ALDH1A1KCNJ1KDM4EMAPT | |
| SCHEMBL1813917 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2315751-A1 | ALKYNYL ALCOHOLS AS KINASE INHIBITORS | Amgen Inc. (US) | 2011-05-04 | — | — | EP | disclosed |
| US-20110086834-A1 | ALKYNYL ALCOHOLS AS KINASE INHIBITORS | AMGEN INC. (US) | 2011-04-14 | — | — | US | disclosed |
| US-20110086834-A1 | ALKYNYL ALCOHOLS AS KINASE INHIBITORS | AMGEN INC. (US) | 2011-04-14 | — | — | US | disclosed |
| WO-2009158011-A1 | ALKYNYL ALCOHOLS AS KINASE INHIBITORS | AMGEN INC. (US) | 2009-12-30 | — | — | WO | disclosed |
| WO-2009158011-A1 | ALKYNYL ALCOHOLS AS KINASE INHIBITORS | AMGEN INC. (US) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086834-A1 | ALKYNYL ALCOHOLS AS KINASE INHIBITORS | NFKBIA, MAP3K1, MAP3K2 | TDP1 925/4885ALDH1A1 1373/4885KCNJ1 3921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.